Skip to main content

Nuvation Bio Inc. (NUVB) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $4.28: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It... Read more

$4.28+154.9% A.UpsideScore 5.0/10#100 of 157 Biotechnology
QualityF-score6 / 9FCF yield-6.65%
Stop $4.00Target $10.73(analyst − 13%)A.R:R 10.7:1
Analyst target$12.33+188.2%9 analysts
$10.73our TP
$4.28price
$12.33mean
$20

Sell if holding. Engine safety override at $4.28: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Nuvation Bio Inc.

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Risk below floor (3.0 < 3.0)

Key Metrics

P/E (TTM)
P/E (Fwd)-72.0
Mkt Cap$1.5B
EV/EBITDA-8.0
Profit Mgn-102.1%
ROE-39.5%
Rev Growth2598.7%
Beta1.52
DividendNone
Rating analysts17

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C1.00neutral
IV72%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
2.2
Macd
3.1
Volume
3.3
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+8.1%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.8<4.5A.R:R 10.7 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 80d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
42 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $4.12Resistance $5.29

Price Targets

$4
$11
A.Upside+150.7%
A.R:R10.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Risk below floor (3.0 < 3.0)
! Momentum score 2.8/10 — below 4.5 minimum

Earnings

M
M
M
M
0/4 beats
Next Earnings2026-08-06 (80d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NUVB stock a buy right now?

Sell if holding. Engine safety override at $4.28: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 10.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $4.00. Score 5.0/10, moderate confidence.

What is the NUVB stock price target?

Take-profit target: $10.73 (+154.9% upside). Prior stop was $4.00. Stop-loss: $4.00.

What are the risks of investing in NUVB?

Risk below floor (3.0 < 3.0).

Is NUVB overvalued or undervalued?

Nuvation Bio Inc. trades at a P/E of N/A (forward -72.0). TrendMatrix value score: 6.6/10. Verdict: Sell.

What do analysts say about NUVB?

17 analysts cover NUVB with a consensus score of 4.1/5. Average price target: $12.

What does Nuvation Bio Inc. do?Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer...

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · HALO (Halozyme Therapeutics, Inc.) · ADMA (ADMA Biologics Inc) · KRYS (Krystal Biotech, Inc.) · INVA (Innoviva, Inc.)